Get the Stockscreener App
9.22
7.08%
0.61
After Hours:
9.22
Oruka Therapeutics Inc stock is traded at $9.22, with a volume of 150.02K.
It is up +7.08% in the last 24 hours and down -22.46% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$8.61
Open:
$8.61
24h Volume:
150.02K
Relative Volume:
0.51
Market Cap:
$304.77M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+25.10%
1M Performance:
-22.46%
6M Performance:
-68.00%
1Y Performance:
+0.00%
1-Day Range:
$8.36
$9.26
1-Week Range:
$7.14
$9.26
52-Week Range:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
9.22 | 304.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Thursday - Defense World
Vanguard Group Inc. Purchases 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - The AM Reporter
Vanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Acquired by Wellington Management Group LLP - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Charles Schwab Investment Management Inc. Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Fairmount Funds Management LLC Increases Stake in Oruka Therapeu - GuruFocus
Oruka Therapeutics Reports Strong 2024 Financial Results - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance - MSN
Comparing Oruka Therapeutics (NASDAQ:ORKA) & Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Earns “Outperform” Rating from Wedbush - Defense World
We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate - Yahoo Finance
Sector Update: Health Care -March 07, 2025 at 03:38 pm EST - Marketscreener.com
Oruka Therapeutics Says ORKA-002 Preclinical Data Support Potential Extended Dosing Intervals - Marketscreener.com
Oruka Therapeutics: Buy Rating Backed by Strong Financials and Promising Clinical Progress - TipRanks
Oruka Therapeutics Announces Preclinical Data for ORKA-002 - GlobeNewswire
Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target - Investing.com
Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target By Investing.com - Investing.com Canada
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - The Manila Times
Oruka Therapeutics Posts Q4 Net Loss -March 06, 2025 at 05:18 pm EST - Marketscreener.com
Oruka Therapeutics reports Q4 EPS (49c), consensus (98c) - TipRanks
Oruka Therapeutics Reports 2024 Financial Results and Progress on Psoriasis Pipeline Including ORKA-001 and ORKA-002 - Nasdaq
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Can Oruka's $394M War Chest Transform Autoimmune Disease Treatment? Key Pipeline Updates - StockTitan
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in Stock - MarketBeat
Insider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of Stock - MarketBeat
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock Healthcare - Investing.com South Africa
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock - Investing.com South Africa
Oruka Therapeutics (ORKA) to Release Earnings on Thursday - Defense World
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewswire
Can This Clinical-Stage Biotech's March Conference Circuit Signal Major Developments? - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) & Alpha Teknova (NASDAQ:TKNO) Head-To-Head Contrast - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
Financial Fitness Check: Examining Oruka Therapeutics Inc (ORKA)’s Key Ratios - The Dwinnex
Oruka Therapeutics Inc (ORKA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Oruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Wolfe Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpTime to Buy? - MarketBeat
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):